21 completed, 21 recruiting, 8 active not recruiting, 6 terminated. 27 Phase 2, 14 Phase 1, 7 Not applicable, 6 Phase 3, 3 Early Phase 1.
Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging ¹⁸F-florbetaben - Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS) | Not applicable | Not yet recruiting | University of Zurich | 50 | 2026-10-01 | 2026-06-03 |
| A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement Anselamimab - AL Amyloidosis | Early Phase 1 | Not yet recruiting | Stanford University | 5 | 2026-09-01 | 2026-10-27 |
| SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders Non-Interventional Study - AL Amyloidosis, Multiple Myeloma | Recruiting | Mayo Clinic | 150 | 2026-08-25 | 2026-09-30 | |
| BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) QLS4131 - AL Amyloidosis | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-07-20 | 2026-08-07 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Teclistamab - Multiple Myeloma, AL Amyloidosis | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 30 | 2026-05-22 | 2026-08-03 |
| Hungarian National Systemic Amyloidosis Registry Systemic Amyloidosis, ATTR Amyloidosis | Recruiting | Semmelweis University | 300 | 2026-03-08 | 2026-07-08 | |
| One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS AL Amyloidosis, POEMS Syndrome | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 100 | 2025-11-28 | 2026-05-06 | |
| Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment AL Amyloidosis, MGUS | Recruiting | Fondazione IRCCS Policlinico San Matteo di Pavia | 100 | 2025-11-17 | 2026-03-04 | |
| BE.Amycon Biobank & Data Registry UZ Leuven Amyloidosis, AL Amyloidosis | Recruiting | Universitaire Ziekenhuizen KU Leuven | 505 | 2025-09-24 | 2026-09-25 | |
| A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis Teclistamab - AL Amyloidosis | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 30 | 2025-07-02 | 2026-07-20 |
| Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis Eque-cel CAR-T Therapy - AL Amyloidosis | Phase 2 | Not yet recruiting | Nanjing IASO Biotechnology Co., Ltd. | 17 | 2025-07-01 | 2025-07-09 |
| Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 35 | 2025-06-28 | 2025-07-23 |
| Teclistamab in Previously Treated AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-05-21 | 2025-05-25 |
| Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis Teclistamab (Tec) - AL Amyloidosis | Not applicable | Recruiting | Peking University People's Hospital | 20 | 2025-03-29 | 2025-04-24 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy CM-336 BCMA/CD3 bispecific antibody - AL Amyloidosis | Not applicable | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-01-01 | 2026-04-29 | |
| Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis Targeted BCMA Autologous CART Cell Injection - Relapsed/Refractory Light Chain Amyloidosis, AL Amyloidosis | Early Phase 1 | Withdrawn | Beijing Boren Hospital | 2024-12-16 | 2026-10-13 | |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis | Phase 3 | Recruiting | SWOG Cancer Research Network | 338 | 2024-07-01 | 2026-05-06 |
Showing 20 of 68. Sign in to see all of them.
Immunoglobulin Light-chain Amyloidosis (68) · Amyloidosis (15) · Multiple Myeloma (10) · Paraproteinemias (7) · Alzheimer Disease (6) · Amyloid Neuropathies, Familial (5) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Monoclonal Gammopathy of Undetermined Significance (3) · Neoplasms, Plasma Cell (2) · Recurrence (2) · Adenine phosphoribosyltransferase deficiency (1) · Amyloidosis, Hereditary, Transthyretin-Related (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Sickle Cell (1)
Immune System Diseases (68) · Immunoproliferative Disorders (68) · Lymphoproliferative Disorders (68) · Metabolic Diseases (68) · Neoplasms (68) · Neoplasms by Histologic Type (68) · Nutritional and Metabolic Diseases (68) · Proteostasis Deficiencies (67) · Neoplasms, Plasma Cell (66) · Paraproteinemias (61) · Amyloidosis (53) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Blood Protein Disorders (15) · Cardiovascular Diseases (12)
Dexamethasone (17) · daratumumab (9) · Bortezomib (7) · Calcium Dobesilate (6) · Cyclophosphamide (5) · pomalidomide (5) · venetoclax (4) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (3) · Focal Adhesion Protein-Tyrosine Kinases (3) · Melphalan (3) · birtamimab (3) · dexamethasone acetate (3) · ixazomib (3) · Bendamustine Hydrochloride (2) · Clinical Protocols (2)
Fondazione IRCCS Policlinico San Matteo di Pavia (8) · Alexion Pharmaceuticals, Inc. (4) · Prothena Biosciences Ltd. (4) · Boston Medical Center (3) · European Myeloma Network B.V. (3) · Peking Union Medical College Hospital (3) · Columbia University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · University of Tennessee (2) · Weill Medical College of Cornell University (2) · Alfred Chung, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Beijing Boren Hospital (1)
United States (36) · Italy (17) · China (11) · France (11) · Germany (11) · Greece (9) · Spain (9) · United Kingdom (9) · Australia (6) · Israel (6) · Austria (5) · Netherlands (5) · Czechia (4) · Belgium (3) · Switzerland (3)
Vaishali Sanchorawala, MD (3) · Scott Swenson, MD (2) · Alfred Chung, MD (1) · Andrew Eisenberger, MD (1) · Andrew Stephens, MD, PhD (1) · Cara Rosenbaum, MD (1) · Craig C Hofmeister, MD, MPH (1) · Dominik C Benz, PD Dr. med. (1) · Don Benson, MD (1) · Frederic Rousseau, Prof. (1) · Giada Bianchi (1) · Giovanni Palladini, MD (1) · Gunjan Shah (1)
PMID 40226119, PMID 42212672, PMID 20085941, PMID 27381904, PMID 28103898, PMID 31151984, PMID 31593552, PMID 31978210, PMID 32083996, PMID 32730181, PMID 34521113, PMID 38148411
P30CA138292 (1), R21CA288898 (1), U10CA180888 (1)